Skip to main content
. 2016 Apr 7;7(4):e2177. doi: 10.1038/cddis.2016.70

Figure 4.

Figure 4

Trametinib and ABT-263 cooperate to kill primary B-ALL cells and delay the onset of leukemia in vivo. (a) Graphs showing viability of purified CD34+ B-ALL cells from five patients 72 h after treatment with trametinib (40 nM) and/or ABT-263 (40 nM). (b) Graphs showing viability of normal CD34+ cells purified from two non-leukemic individuals 72 h after treatment with trametinib (40 nM) and/or ABT-263 (40 nM). Results are shown as percentage of cell viability relative to dimethyl sulfoxide control. Error bars: S.E.M. (c) Kaplan–Meier survival curves showing leukemia-free survival of mice inoculated with 697 cells and treated with vehicle, trametinib (0.15 mg/Kg), ABT-263 (100 mg/Kg), or trametinib (0.15 mg/Kg) plus ABT-263 (100 mg/Kg) for 3 weeks. (d) Scatter dot plot showing human CD19+ cells (%) measured by flow cytometry in the bone marrow of the mice at death in each treatment arm shown in panel (c). Error bars: mean with 95% confidence intervals. *P<0.05; **P<0.01; NS, not significant